Compare IDEXX Laboratories, Inc. (IDXX) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs KeyCorp — how do they compare? IDEXX Laboratories, Inc. trades at $578.6 (market cap $46.22B), while KeyCorp trades at $22.73 (market cap $24.32B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and KeyCorp pays a 3.61% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | KEY | |
|---|---|---|
Market Cap | $46.22B | $24.32B |
Sector | Health | Financials |
52-Week High | $766.68 | $23.99 |
52-Week Low | $526.44 | $16.78 |
Enterprise Value | $47.12B | — |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
KeyCorp (KEY) trades at $22.68, down 0.22% on the day, with a bearish technical signal but strong fundamental recovery. The company reported Q2 2026 EPS of $0.44, beating estimates, and shows robust revenue growth to $7.29B in 2025. Recent expansion includes the acquisition of Clearwater UK, enhancing its investment banking footprint.
The outlook is positive with a consensus price target of $29.41, representing significant upside. Risks include economic uncertainty impacting loan growth and net interest income. The stock offers a dividend yield supported by consistent payouts, with analyst sentiment strongly favoring a buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
